hIRK: A GPCR Targeted for Drug Development and Biomarker Research

Target Name: KCNJ12

NCBI ID: G3768

KCNJ12

hIRK: A GPCR Targeted for Drug Development and Biomarker Research

hIRK, also known as KCNJ12, is a G protein-coupled receptor located on the surface of various cell types in the body. It plays a crucial role in neural signaling and has been linked to various neurological and psychiatric disorders. Despite its importance, hIRK is not well understood, and research into its potential drug targets or biomarkers is limited. In this article, we will explore hIRK and its potential as a drug target, as well as its potential as a biomarker for various psychiatric and neurological disorders.

hIRK is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a vital role in cellular signaling. GPCR are involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and hormone signaling. hIRK is specifically involved in neurotransmitter signaling, particularly the release of neurotransmitters such as dopamine, serotonin, and endocannabinoids.

One of the key functions of hIRK is its role in neurotransmitter signaling is to regulate the release of neurotransmitters from the axon terminal of neurons. It does this by interacting with the postsynaptic density (PSD), which is the protein that forms the boundary between the axon terminal of the neuron and the dendrites. The PSD contains a protein called PSD-95, which is known to interact with hIRK. When hIRK is activated, it causes PSD-95 to translocate to the axon terminal, where it can interact with the neurotransmitter receptors, leading to the release of the neurotransmitter.

Another function of hIRK is its role in the modulation of pain perception. hIRK has been shown to be involved in the modulation of pain sensitivity in various experimental models, including models of neuropathic pain and chronic pain. It is thought to work by modulating the activity of pain-related neurons, which can either enhance or reduce pain sensitivity, depending on the context.

hIRK is also involved in the regulation of anxiety and depression. Studies have shown that hIRK is involved in the modulation of anxiety- and depression-related behaviors, as well as the regulation of neurotransmitter systems. For example, hIRK has been shown to play a role in the regulation of the release of neurotransmitters such as dopamine and serotonin, which are involved in the regulation of mood and anxiety.

In addition to its role in neurotransmitter signaling, hIRK has also been shown to have potential as a biomarker for various psychiatric and neurological disorders. For example, hIRK has been shown to be involved in the regulation of the release of neurotransmitters in individuals with depression, and has been shown to be associated with an increased risk of developing depression. Additionally, hIRK has also been shown to be involved in the regulation of pain sensitivity, which is often elevated in individuals with anxiety and depression.

Despite its potential as a drug target and biomarker, hIRK is still not well understood. There are currently no known drugs that specifically target hIRK, and research into its potential drug targets or biomarkers is limited. However, hIRK is a promising target for future research, as its role in neurotransmission and its potential as a biomarker for psychiatric and neurological disorders make it a valuable study object.

In conclusion, hIRK is a GPCR located on the surface of various cell types in the body that plays a crucial role in neural signaling. Its function is closely related to neurotransmitter signaling, particularly the release of neurotransmitters such as dopamine, serotonin, and endocannabinoids. hIRK is also involved in the modulation of pain perception and has been shown to be involved in the regulation of anxiety and depression. Despite its potential as a drug target and biomarker, hIRK is still not well understood and research into its functions is limited. Further studies are needed to fully understand hIRK's role in neural signaling and its potential as a drug target

Protein Name: Potassium Inwardly Rectifying Channel Subfamily J Member 12

Functions: Inward rectifying potassium channel that is activated by phosphatidylinositol 4,5-bisphosphate and that probably participates in controlling the resting membrane potential in electrically excitable cells. Probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium

The "KCNJ12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNJ12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets